Biotherapy of cancer by anti-EGFR monoclonal antibody / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1135-1138, 2007.
Artículo
en Chino
| WPRIM
| ID: wpr-318773
ABSTRACT
Epidermal growth factor receptor (EGFR) is mutated, dysregulated or overexpressed in many epithelial malignancies, and EGFR activation has been found to be important in tumor growth and progression. Anti-EGFR monoclonal antibodies target the extracellular domain of EGFR; and show promising anti-tumor potential at clinical trials without severe side effects. In this article the pharmacokenetics and clinical study of 3 anti-EGFR monoclonal antibodies (cetuximab, panitumumab and nimotuzomab) were reviewed.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Terapéutica
/
Farmacocinética
/
Usos Terapéuticos
/
Alergia e Inmunología
/
Anticuerpos Monoclonales Humanizados
/
Receptores ErbB
/
Cetuximab
/
Anticuerpos Monoclonales
/
Neoplasias
/
Antineoplásicos
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2007
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS